4 results match your criteria: "THR Presbyterian Hospital.[Affiliation]"
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.
Expert Rev Mol Diagn
January 2022
Data Science, Scipher Medicine, Waltham, MA, USA.
Background: The molecular signature response classifier (MSRC) is a blood-based precision medicine test that predicts nonresponders to tumor necrosis factor-ɑ inhibitors (TNFi) in rheumatoid arthritis (RA) so that patients with a molecular signature of non-response to TNFi can be directed to a treatment with an alternative mechanism of action.
Research Design And Methods: This study evaluated decision choice and treatment outcomes resulting from MSRC-informed treatment selection within a real-world cohort.
Results: Therapy selection by providers was informed by MSRC results for 73.
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Curr Opin Rheumatol
May 2021
Rheumatology Department, THR Presbyterian Hospital.
Article Synopsis
- Recent articles review the use of Janus Kinase inhibitors (Jaki) for treating rheumatoid arthritis (RA) in patients who have not responded to conventional treatments (csDMARDs).
- EULAR and ACR have updated guidelines recommending Jaki use after csDMARD failure, highlighting their efficacy as monotherapy versus combination therapy.
- Jaki are becoming a common alternative to biologics, though there are concerns about increased risks of venous thromboembolism (VTE) and conflicting data on this risk, with ongoing research into strategies for optimizing treatment.
JAK inhibitors and VTE risk: how concerned should we be?
Nat Rev Rheumatol
March 2021
Metroplex Clinical Research Center, Rheumatology Department, THR Presbyterian Hospital, Dallas, TX, USA.
Subcutaneous occipital region stimulation for intractable headache syndromes.
Prog Neurol Surg
March 2012
Department of Neurosurgery, THR Presbyterian Hospital, Dallas, Tex., USA.
Subcutaneous occipital nerve region stimulation is becoming an important part of the overall treatment regimen for a number of chronic headache syndromes refractory to nonsurgical, medical management. A combination of improved device technology and methodology, further understanding about appropriate indications and achievement of on-label FDA status should support continued use and success of this neuromodulation modality.
View Article and Find Full Text PDF